US OptionsDetailed Quotes
ESPR250117C2000
- 0.60
- +0.05+9.09%
15min DelayClose Nov 22 16:00 ET
0.69High0.60Low
0.60Open0.55Pre Close139 Volume25.40K Open Interest2.00Strike Price8.93KTurnover82.70%IV3.17%PremiumJan 17, 2025Expiry Date0.52Intrinsic Value100Multiplier53DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type0.8181Delta0.3310Gamma4.03Leverage Ratio-0.0021Theta0.0021Rho3.30Eff Leverage0.0025Vega
Esperion Therapeutics Stock Discussion
Sign in to post a comment
$Esperion Therapeutics (ESPR.US)$
someone loaded 520k at close 👀👀👀👀
someone loaded 520k at close 👀👀👀👀
2
$Esperion Therapeutics (ESPR.US)$ need to increase my holding for a decent Xmas meal….maybe next year
1
$Esperion Therapeutics (ESPR.US)$
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
Esperion (ESPR) presented new exploratory data from the CLEAR Outcomes trial at the 2024 AHA Scientific Sessions, highlighting significant benefits of NEXLETOL (bempedoic acid).
The analysis showed patients with Peripheral Artery Disease (PAD) tak...
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
Esperion (ESPR) presented new exploratory data from the CLEAR Outcomes trial at the 2024 AHA Scientific Sessions, highlighting significant benefits of NEXLETOL (bempedoic acid).
The analysis showed patients with Peripheral Artery Disease (PAD) tak...
2
2
This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...
+18
15
1
$Esperion Therapeutics (ESPR.US)$ this zone level 2.600 possibility price reject. due to high volume
$Esperion Therapeutics (ESPR.US)$ $10 …. 🚀🚀🚀
1
1
No comment yet
Rich2023 : If acquired by a large company, the price could be between $9-15, even $20.
老实和尚 : Look at other stocks, most of them end the day like this. There's nothing special, it may just be a closing mechanism.